SHSE:600276 (China)
Â
Class A
Â¥
53.45
-1.46 (-2.66%)
Jul 24
Business Description
Jiangsu Hengrui Pharmaceuticals Co Ltd
ISIN : CNE0000014W7
Share Class Description:
SHSE:600276: Class ATotal Employee Number:
20,602Compare
Compare
Traded in other countries / regions
600276.China01276.Hong Kong1276N.Mexico0BO.GermanyJHPCY.USA Index Membership
SSE Composite IndexCSI 300 Index IPO Date
2000-10-18Description
Jiangsu Hengrui Pharmaceuticals Co Ltd is a biopharmaceutical company that engages in the research, development, manufacture, and sale of drugs. It is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs, and anti-infection medications. The company specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system. Geographically, the company is segmented as Chinese mainland and Other countries generating majority revenue from the Chinese region.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 602.24 | |||||
Equity-to-Asset | 0.89 | |||||
Debt-to-EBITDA | 0.01 | |||||
Interest Coverage | 2364.63 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 32.17 | |||||
Beneish M-Score | -2.85 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 13.4 | |||||
3-Year EBITDA Growth Rate | 27.2 | |||||
3-Year EPS without NRI Growth Rate | 28.3 | |||||
3-Year Book Growth Rate | 15.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 18.91 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 14.43 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 36.75 | |||||
9-Day RSI | 45.63 | |||||
14-Day RSI | 49.44 | |||||
3-1 Month Momentum % | -10.35 | |||||
6-1 Month Momentum % | -14.82 | |||||
12-1 Month Momentum % | -12.61 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 9.23 | |||||
Quick Ratio | 8.72 | |||||
Cash Ratio | 7.21 | |||||
Days Inventory | 224.53 | |||||
Days Sales Outstanding | 56.3 | |||||
Days Payable | 183.56 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.36 | |||||
Dividend Payout Ratio | 0.17 | |||||
3-Year Dividend Growth Rate | 7.7 | |||||
Forward Dividend Yield % | 0.36 | |||||
5-Year Yield-on-Cost % | 0.47 | |||||
3-Year Average Share Buyback Ratio | -1.3 | |||||
Shareholder Yield % | 0.38 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 86.54 | |||||
Operating Margin % | 28.12 | |||||
Net Margin % | 24.93 | |||||
EBITDA Margin % | 28.23 | |||||
FCF Margin % | 26.11 | |||||
OCF Margin % | 35.21 | |||||
ROE % | 14.01 | |||||
ROA % | 12.54 | |||||
ROIC % | 33.11 | |||||
3-Year ROIIC % | 214.14 | |||||
ROC (Joel Greenblatt) % | 77.47 | |||||
ROCE % | 15.48 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 7 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 43.81 | |||||
Forward PE Ratio | 37.51 | |||||
PE Ratio without NRI | 44.69 | |||||
Shiller PE Ratio | 65.99 | |||||
Price-to-Owner-Earnings | 57.29 | |||||
PEG Ratio | 5.38 | |||||
PS Ratio | 10.91 | |||||
PB Ratio | 5.57 | |||||
Price-to-Tangible-Book | 6.31 | |||||
Price-to-Free-Cash-Flow | 41.5 | |||||
Price-to-Operating-Cash-Flow | 30.86 | |||||
EV-to-EBIT | 35.14 | |||||
EV-to-Forward-EBIT | 51.72 | |||||
EV-to-EBITDA | 35.14 | |||||
EV-to-Forward-EBITDA | 45.73 | |||||
EV-to-Revenue | 9.92 | |||||
EV-to-Forward-Revenue | 9.83 | |||||
EV-to-FCF | 38 | |||||
Price-to-GF-Value | 0.88 | |||||
Price-to-Projected-FCF | 4.06 | |||||
Price-to-DCF (Earnings Based) | 2.9 | |||||
Price-to-DCF (FCF Based) | 3.6 | |||||
Price-to-Median-PS-Value | 0.86 | |||||
Price-to-Peter-Lynch-Fair-Value | 3.79 | |||||
Price-to-Graham-Number | 3.54 | |||||
| Price-to-Net-Current-Asset-Value | 7.99 | |||||
| Price-to-Net-Cash | 10.75 | |||||
Earnings Yield (Greenblatt) % | 2.85 | |||||
FCF Yield % | 2.41 | |||||
Forward Rate of Return (Yacktman) % | 13 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Jiangsu Hengrui Pharmaceuticals Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 32,564.37 | ||
| EPS (TTM) (Â¥) | 1.22 | ||
| Beta | 1.0138 | ||
| 3-Year Sharpe Ratio | 0.09 | ||
| 3-Year Sortino Ratio | 0.14 | ||
| Volatility % | 28.68 | ||
| 14-Day RSI | 49.44 | ||
| 14-Day ATR (Â¥) | 2.35013 | ||
| 20-Day SMA (Â¥) | 54.7845 | ||
| 12-1 Month Momentum % | -12.61 | ||
| 52-Week Range (Â¥) | 45.26 - 74.04 | ||
| Shares Outstanding (Mil) | 6,637.2 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Jiangsu Hengrui Pharmaceuticals Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Jiangsu Hengrui Pharmaceuticals Co Ltd Stock Events
| Event | Date | Price (Â¥) | ||
|---|---|---|---|---|
| CNY 0.200000 Cash Dividend | 2026-05-27 | 49.20 (+0.24%) | ||
| CNY 0.200000 Cash Dividend | 2025-05-23 | 55.60 (-0.71%) | ||
| 1.2:1 Stock Split | 2021-06-10 | 70.13 (+1.28%) | ||
| 1.2:1 Stock Split | 2020-05-25 | 66.58 (-3.90%) | ||
| 1.2:1 Stock Split | 2019-03-28 | 43.03 (+3.08%) | ||
| 1.3:1 Stock Split | 2018-05-30 | 42.48 (-4.82%) | ||
| 1.2:1 Stock Split | 2017-05-31 | 21.85 (+0.49%) | ||
| 1.2:1 Stock Split | 2016-06-16 | 14.28 (+0.90%) | ||
| 1.3:1 Stock Split | 2015-06-15 | 14.86 (-0.03%) | ||
| 1.1:1 Stock Split | 2014-05-15 | 7.42 (+1.09%) |
Show
Entries
Jiangsu Hengrui Pharmaceuticals Co Ltd Frequently Asked Questions
What is Jiangsu Hengrui Pharmaceuticals Co Ltd(SHSE:600276)'s stock price today?
The current price of SHSE:600276 is ¥53.45. The 52 week high of SHSE:600276 is ¥74.04 and 52 week low is ¥45.26.
When is next earnings date of Jiangsu Hengrui Pharmaceuticals Co Ltd(SHSE:600276)?
The next earnings date of Jiangsu Hengrui Pharmaceuticals Co Ltd(SHSE:600276) is .
Does Jiangsu Hengrui Pharmaceuticals Co Ltd(SHSE:600276) pay dividends? If so, how much?
The Dividend Yield %  of Jiangsu Hengrui Pharmaceuticals Co Ltd(SHSE:600276) is 0.36% (As of Today), Highest Dividend Payout Ratio of Jiangsu Hengrui Pharmaceuticals Co Ltd(SHSE:600276) was 0.3. The lowest was 0.08. And the median was 0.18. The  Forward Dividend Yield % of Jiangsu Hengrui Pharmaceuticals Co Ltd(SHSE:600276) is 0.36%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Articles on Jiangsu Hengrui Pharmaceuticals Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers